MedPath

Nanofat Grafting as a Method of Treating Critical Limb Ischemia

Not Applicable
Not yet recruiting
Conditions
Limb Ischemia
Interventions
Procedure: sham comparator
Procedure: nano-fat grafting in chronic limb ischaemia
Registration Number
NCT06357936
Lead Sponsor
Center of New Medical Technologies
Brief Summary

This clinical trial will investigate nano fat grafting as a method for treating critical limb ischemia. The method involves the collection of adipose tissue under tumescent anesthesia through a separate incision in the anterior abdominal wall, followed by preparation and injection of nano fat into the tissues of the foot and leg without additional drug therapy. The novelty of this method lies in the use of autologous stem cells and growth factors, differing from current treatments like neovasculgen, which is a plasmid DNA-based treatment. The trial aims to assess the safety and effectiveness of nano fat grafting, including pain relief, the frequency of intraoperative complications, increased distance of pain-free walking, limb preservation, and mortality rates.

The trial will involve patients with diagnosed occlusive lesions of the femoral-popliteal-tibial segment and chronic ischemia of III-IV degree according to Fontaine and 5-6 categories according to Rutherford, excluding those with contraindications for surgical intervention on the femoral-popliteal-tibial segment, chronic heart failure of III-IV NYHA class, severe liver or kidney failure, among others.

The study design includes preoperative examinations, hospital phase activities including the surgery and post-operative assessments, and follow-up visits at 6 and 12 months post-operation to evaluate the method's safety, complications, and effectiveness based on various parameters like pain, trophic disturbances, and limb ischemia severity.

Statistical methods will involve quantitative data presented as mean ± standard deviation, with qualitative traits compared using the Chi-square test or Fisher's exact test. The planned patient number is 40, aiming to demonstrate the effectiveness and safety of nano fat grafting for critical limb ischemia treatment compared to current treatments.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Patients with occlusive lesions of the femoral-popliteal-tibial segment.
  • Chronic ischemia of the lower limbs of III-IV degree according to Fontaine and categories 5-6 according to Rutherford.
  • Signed informed consent for participation in the clinical trial.
Exclusion Criteria
  • Absence of indications for surgical intervention on the femoral-popliteal-tibial segment.
  • Patients refusing to participate in the clinical trial.
  • Chronic heart failure of III-IV NYHA functional class.
  • Chronic decompensated "pulmonary" heart.
  • Severe liver or kidney failure (bilirubin >35 mmol/L, glomerular filtration rate <60 ml/min).
  • Polivalent drug allergy.
  • Malignant oncological diseases in the terminal stage with a life expectancy of less than 6 months.
  • Acute cerebrovascular accident.
  • Decompensated diseases of the endocrine organs (for diabetes, glycemia level more than 10 mmol/L).
  • Pregnancy and lactation period.
  • Inability to undergo examinations at control points.
  • Refusal to sign informed consent for participation in the clinical trial.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
standard therapy groupsham comparator-
nano fat grafting groupnano-fat grafting in chronic limb ischaemia-
Primary Outcome Measures
NameTimeMethod
Percent of pain absence in experimental group12 months
Secondary Outcome Measures
NameTimeMethod
Number of any intraoperative complications12 months
Number of any inhospital complications12 months
Percent change in visual analog pain score (VAS) change12 months

The Visual Analogue Scale (VAS) is a straightforward, tool for measuring pain intensity or other subjective experiences that are difficult to quantify, such as fatigue or nausea. It consists of a straight line, usually 10 centimeters (100 millimeters) long, anchored by two descriptors defining the extremes of the experience being measured (e.g., "no pain" on one end and "worst imaginable pain" on the other for pain measurement).. The result is typically recorded in millimeters, with scores ranging from 0 to 100, where 0 represents one extreme (e.g., no pain) and 100 represents the other (e.g., worst imaginable pain).

Number of saved limbs12 months

Trial Locations

Locations (1)

Center of New Medical Technologies

🇷🇺

Novosibirsk, Novosibirsk Region, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath